Angina in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

Angina Angina pectoris Aortic valve stenosis Coronary artery disease Enfermedad coronaria Estenosis aórtica Implante percutáneo de valvula aórtica Transcatheter aortic valve replacement

Journal

Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 15 01 2023
accepted: 03 04 2023
medline: 28 11 2023
pubmed: 4 5 2023
entrez: 3 5 2023
Statut: ppublish

Résumé

To evaluate the prevalence, clinical characteristics, and outcomes of patients with angina undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. A total of 1687 consecutive patients with severe aortic stenosis undergoing TAVR at our center were included and classified according to patient-reported angina symptoms prior to the TAVR procedure. Baseline, procedural and follow-up data were collected in a dedicated database. A total of 497 patients (29%) had angina prior to the TAVR procedure. Patients with angina at baseline showed a worse New York Heart Association (NYHA) functional class (NYHA class> II: 69% vs 63%; P=.017), a higher rate of coronary artery disease (74% vs 56%; P <.001), and a lower rate of complete revascularization (70% vs 79%; P <.001). Angina at baseline had no impact on all-cause mortality (HR, 1.02; 95%CI, 0.71-1.48; P=.898) and cardiovascular mortality (HR, 1.2; 95%CI, 0.69-2.11; P=.517) at 1 year. However, persistent angina at 30 days post-TAVR was associated with increased all-cause mortality (HR, 4.86; 95%CI, 1.71-13.8; P=.003) and cardiovascular mortality (HR, 20.7; 95%CI, 3.50-122.6; P=.001) at 1-year follow-up. More than one-fourth of patients with severe aortic stenosis undergoing TAVR had angina prior to the procedure. Angina at baseline did not appear to be a sign of a more advanced valvular disease and had no prognostic impact; however, persistent angina at 30 days post-TAVR was associated with worse clinical outcomes.

Identifiants

pubmed: 37137426
pii: S1885-5857(23)00113-5
doi: 10.1016/j.rec.2023.04.004
pii:
doi:

Types de publication

Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

991-1002

Informations de copyright

Copyright © 2023 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

Lukas S Keller (LS)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Jorge Nuche (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Marisa Avvedimento (M)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Carlos Real (C)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Julio Farjat-Pasos (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Jean-Michel Paradis (JM)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Robert DeLarochellière (R)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Anthony Poulin (A)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Dimitris Kalavrouziotis (D)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Eric Dumont (E)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Attilio Galhardo (A)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Siddhartha Mengi (S)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Siamak Mohammadi (S)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada. Electronic address: josep.rodes@criucpq.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH